Adjuvant Trials

1. Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)
 
            ClinicalTrials.gov Identifier                         NCT03447769         
 
This study is currently recruiting. 
 
A study to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).
 
Alberta
Edmonton, Alberta, Canada, T6G 1Z2

New Brunswick
Moncton, New Brunswick, Canada, E1C 6Z8
 
Ontario
Hamilton, Ontario, Canada, L8V 5C2
 
Quebec
Montreal, Quebec, Canada, H2W 1T8
Quebec City, Quebec, Canada, GIV 4G5

2. Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC     
 
                     ClinicalTrials.gov Identifier                                NCT02273375           

This study is active but not currently recruiting.

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (possibly chemotherapy) for lung cancer.   

Newfoundland
Dr. H. Bliss Murphy Cancer Centre
St. Johns, Newfoundland and Labrador, A1B 3V6

Ontario
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
 
Kingston Health Sciences Centre
Kingston, Ontario, Canada, K7L 2V7
 
London Regional Cancer Program
London, Ontario, Canada, N6A 5W9
 
Stronach Regional Health Centre at Southlake
Newmarket, Ontario, Canada, L3Y 2P9
 
Lakeridge Health Oshawa
Oshawa, Ontario, Canada, L1G 2B9
 
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
 
Algoma District Cancer Program
Sault Ste. Marie, Ontario, Canada, P6B 0A8
 
Niagara Health System
St. Catharines, Ontario, Canada, L2S 0A9
 
Health Sciences North
Sudbury, Ontario, Canada, P3E 5J1
 
Thunder Bay Regional Health Sciences Centre/Thunder
Thunder Bay, Ontario, Canada, P7B 6V4
 
Humber River Hospital
Toronto, Ontario, Canada, M3M 0B2
 
Odette Cancer Centre
Toronto, Ontario, Canada, M4N 3M5
 
Sinai Health System
Toronto, Ontario, Canada, M5G 1X5
 
University Health Network
Toronto, Ontario, Canada, M5G 2M9
 
Quebec
McGill University - Dept. Oncology 
Montreal, Quebec, H2W 1S6

Saskatchewan 
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1

Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4

Alberta
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2

Tom Baker Cancer Center
Calgary, Alberta, T2N 4N2

Nova Scotia 
QE II Health Sciences Center 
Halifax, Nova Scotia, B3H 2Y9

British Columbia
BCCA - Abbotsford Centre
Abbotsford, British Columbia, Canada, V2S 0C2

BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada, V3V 1Z2

BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6

Manitoba
CancerCare Manitoba 
Winnipeg, Manitoba, Canada, R3E 0V9 

New Brunswick 
The Moncton Hospital
Moncton, New Brunswick, Canada, E1C 6Z8

Regional Health Authority B, Zone 2
Saint John, New Brunswick, Canada, E2L 4L2

Prince Edward Island
PEI Cancer Treatment Centre
Charlottetown, Prince Edward Island, Canada, C1A 8T5

Quebec
Levis, Quebec, Canada, G6V 3Z1
 
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada, H2X 3E4
 
The Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
 
The Research Institute of the McGill University
Montreal, Quebec, Canada, H4A 3J1
 
Centre Integre Universitaire De Sante Et De Services
Montreal, Quebec, Canada, H4J 1C5
 
University Institute of Cardiology and
Quebec City, Quebec, Canada, G1V 4G5

Saskatchewan
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada, S4T 7T1
 
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada, S7N 4H4

3. AZD9291 Versus Placebo in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma, Folowing Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA) 
 
            ClinicalTrials.gov Identifier                         NCT02511106         

This study is active but not currently recruiting. 

A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA)

Ontario
Research Site
Toronto, Ontario, Canada, M5G 2M9